Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure

International Journal of Cardiology

Volumn 159, Issue 1, 2012, Pages 21-28

  Núñez, Julio ^a   Núñez, Eduardo ^a   Sanchis, Juan ^a   Bodí, Vicent ^a   Fonarow, Gregg C ^b   Miñana, Gema ^a   Palau, Patricia ^a   Bertomeu González, Vicente ^c   Carratalá, Arturo ^d   Mainar, Luis ^e   Chorro, Francisco J ^a   Llàcer, Angel ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^d Hosp Clin Univ   (Spain)

^e HOSPITAL DE MANISES   (Spain)

Author keywords

Acute heart failure; Antigen carbohydrate 125; Brain natriuretic peptide; Mortality; Serial measurements

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CA 125 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ACUTE HEART FAILURE; AGED; AMBULATORY CARE; ANTIGEN DETECTION; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CA-125 ANTIGEN; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RISK FACTORS;

EID: 84863783837     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.02.001     Document Type: Article

References (38)

1. Fang J, Mensah GA, Croft JB, et al. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008;52:428-34. (Pubitemid 352040814)
2. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-e146.
3. Núñez J, Núñez E, Robles R, et al. Prognostic value of brain natriuretic peptide in acute heart failure: mortality and hospital readmission. Rev Esp Cardiol 2008;61: 1332-7.
4. Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007;49:1943-50. (Pubitemid 46694287)
5. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635-41. (Pubitemid 38229537)
6. Daniels LB, Clopton P, Jiang K, et al. Prognosis of stage A or B heart failure patients with elevated B-type natriuretic peptide levels. J Card Fail 2010;16:93.7-8.7.
7. Richards AM. Serial measurements of plasma B-type natriuretic peptides: what do they tell us? J Am Coll Cardiol 2008;52:1004-5.
8. Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008;52:997-1003.
9. Núñez J, Núñez E, Consuegra L, et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart 2007;93:716-21. (Pubitemid 46808274)
10. D'Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003;41:1805-11. (Pubitemid 36584256)
11. Núñez J, Sanchis J, Bodí V, et al. Improvement in risk stratification with the combination of the tumor marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 2010;31:1752-63.
12. Nägele H, Bahlo M, Klapdor R, et al. CA 125 and its relation to cardiac function. Am Heart J 1999;137:1044-9. (Pubitemid 30040726)
13. Turgut O, Tandogan I, Yilmaz MB, et al. CA125 levels among patients with advanced heart failure: an emerging independent predictor for survival. Int J Cardiol 2009;145:71.
14. Miñana G, Núñez J, Sanchis J, et al. CA125 and immunoinflammatory activity in acute heart failure. Int J Cardiol 2010;145:547-8.
15. Varol E, Ozaydin M, Dogan A, et al. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 2005;7:840-3. (Pubitemid 41125903)
16. Turk HM, Pekdemir H, Buyukberber S, et al. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 2003;24:172-5. (Pubitemid 37500565)
17. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339: 321-8. (Pubitemid 28366422)
18. Bidart JM, Thuillier F, Augereau C, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999;45: 1695-707. (Pubitemid 29477325)
19. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 2005;26:384-416.
20. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
21. Latini R, Masson S, Wong M, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006;119(70):e23-30.
22. Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Chichester, UK: Wiley; 2008.
23. Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72 discussion 207-12.
24. O'Brien RJ, Squire IB, Demme B, et al. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 2003;5: 499-506. (Pubitemid 37021644)
25. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168-74. (Pubitemid 39372496)
26. Bayés-Genís A, Lopez L, Zapico E, et al. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail 2005;11:S3-8.
27. Cohen-Solal A, Logeart D, Huang B, et al. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 2009;53:2343-8.
28. Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 2007;116:249-57. (Pubitemid 47196560)
29. Cleland J, Freemantle N, Ghio S, et al. Predicting the long-term effects of cardiac resynchronisation therapy on mortality from baseline variables and the early response. A report from CARE-HF (Cardiac Resynchronisation in Heart Failure). J Am Coll Cardiol 2008;52:438-45. (Pubitemid 352040815)
30. Olsson LG, Swedberg K, Cleland JG, et al. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a b-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. Eur J Heart Fail 2007;9: 795-801. (Pubitemid 47225165)
31. Kubánek M, Goode KM, Lánská V, et al. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 2009;11:367-77.
32. Moertl D, Hammer A, Huelsmann M, et al. Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients. Eur J Heart Fail 2008;10:404-11.
33. Cotter G, Metra M, Milo-Cotter O, et al. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008;10:165-9. (Pubitemid 351222743)
34. Colombo PC, Jorde UP. The active role of venous congestion in the pathophysiology of acute decompensated heart failure. Rev Esp Cardiol 2010;63:5-8.
35. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000;140: 840-7.
36. Nägele H, Bahlo M, Klapdor R, et al. Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Anticancer Res 1999;19:2531-4. (Pubitemid 29392407)
37. Faggiano P, D'Aloia A, Brentana L, et al. Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 2005;7:57-61. (Pubitemid 40092492)
38. Shewan LG, Coats AJ. Ethics in the authorship and publishing of scientific articles Int J Cardiol 2010;144:1-2.